Filana Therapeutics Inc (FLNA)

$1.18 -0.01 (-0.84%)
Market Cap 59.90M
Revenue (ttm) 0.00
Net Income (ttm) -90.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 207,300
Avg Vol 402,996
Day's Range N/A - N/A
Shares Out 48.31M
Stochastic %K 6%
Beta -0.72
Analysts Strong Sell
Price Target $6.50

Company Profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its na...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 501 2444
Address:
6801 N. Capital of Texas Highway, Building 1, Austin, United States
MainStreetProdigy
MainStreetProdigy Jun. 24 at 8:09 PM
$FLNA Tick, tock, tick, tock.. ⏰ "Wise man say: Forgiveness is divine, but never pay full price for late pizza" 🍕 We’re still waiting on the PR announcing the FDA releasing their clinical hold.. THE CLOCK IS TICKING DUDE as the stock price implodes! 🤦🏼‍♂️ 💣
0 · Reply
PeterRaslow
PeterRaslow Jun. 23 at 6:34 PM
$FLNA U guys remember Tiffany and Matt nachtrab They got us good
0 · Reply
wintogether
wintogether Jun. 22 at 4:32 PM
$SPCX SAVA 2.0? $FLNA
0 · Reply
PeterRaslow
PeterRaslow Jun. 16 at 9:29 PM
$SLS this guy was posting the same on $SAVA now $FLNA he dissappeared like a shit stain in the wash, got promoted to working SLS now
0 · Reply
donrubin
donrubin Jun. 16 at 8:16 PM
$FLNA it won't move before we see Form 4's.
0 · Reply
To_De_Moon
To_De_Moon Jun. 16 at 3:54 PM
$FLNA 🔥
0 · Reply
Bricktop200
Bricktop200 Jun. 16 at 8:37 AM
$FLNA I don’t care how much red I’m seeing here, end goal is the hold being lifted which I believe it will be.
1 · Reply
focafoca99
focafoca99 Jun. 15 at 10:40 AM
$FLNA approved an amendment to its 2018 Omnibus Incentive Plan, boosting authorized shares by 4 million and extending the plan to 2030. https://www.rapidticker.com/news/flna-sec-filing-fb5490
0 · Reply
ZacksResearch
ZacksResearch Jun. 12 at 3:56 PM
$FLNA Gains 5.7% in a Month 💰 $FLNA just made its case for simufilam stronger — but the FDA hurdle remains 👀 📚 New preclinical data published in Epilepsia showed simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. 🧪 The company also highlighted its TSC-related epilepsy program at Eilat XVIII and is actively working to address the FDA’s Clinical Hold through additional pre-clinical data and protocol modifications. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/FLNA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38403&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38403
1 · Reply
PeterRaslow
PeterRaslow Jun. 11 at 4:04 PM
$FLNA we will cure Alzheimer's with simifilam
2 · Reply
Latest News on FLNA
Filana Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:30 AM EDT - 13 days ago

Filana Therapeutics Transcript: AGM 2026

Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot

2026-05-26T13:58:44.000Z - 4 weeks ago

Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot

Filana Therapeutics resumed with a Buy at Maxim

2026-05-26T12:40:15.000Z - 4 weeks ago

Filana Therapeutics resumed with a Buy at Maxim

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Filana Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Filana Therapeutics Earnings release: Q1 2026

Filana Therapeutics Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Filana Therapeutics Quarterly report: Q1 2026

Filana Therapeutics Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Filana Therapeutics Slides: Corporate presentation

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Filana Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Filana Therapeutics Proxy statement: Proxy filing

Filana Therapeutics publishes simufilam preclinical data

2026-04-15T12:20:15.000Z - 2 months ago

Filana Therapeutics publishes simufilam preclinical data

Filana Therapeutics management to meet with Maxim

2026-03-19T19:25:18.000Z - 3 months ago

Filana Therapeutics management to meet with Maxim

Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year

2026-03-12T12:13:27.000Z - 3 months ago

Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year

Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M

2026-03-12T12:12:53.000Z - 3 months ago

Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M

Filana Therapeutics Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Filana Therapeutics Annual report: Q4 2025

Filana Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Filana Therapeutics Earnings release: Q4 2025

Filana Therapeutics Slides: Investor presentation

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Filana Therapeutics Slides: Investor presentation

Cassava Sciences says US DOJ has closed investigation into company

Feb 19, 2026, 8:52 AM EST - 4 months ago

Cassava Sciences says US DOJ has closed investigation into company

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 11:51 AM EST - 6 months ago

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Filana Therapeutics Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 7 months ago

Filana Therapeutics Registration statement: Registration Filing

Filana Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Filana Therapeutics Quarterly report: Q3 2025

Filana Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Filana Therapeutics Earnings release: Q3 2025

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:05 PM EDT - 8 months ago

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Filana Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 5:00 PM EDT - 10 months ago

Filana Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Filana Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Filana Therapeutics Quarterly report: Q2 2025

Filana Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Filana Therapeutics Earnings release: Q2 2025

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Aug 4, 2025, 7:30 AM EDT - 11 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Filana Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Filana Therapeutics Quarterly report: Q1 2025

Filana Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Filana Therapeutics Earnings release: Q1 2025

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025, 7:30 AM EDT - 1 year ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Apr 21, 2025, 4:30 PM EDT - 1 year ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Filana Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Filana Therapeutics Proxy statement: Proxy Filing

Filana Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Filana Therapeutics Proxy statement: Proxy Filing

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 26, 2025, 3:49 PM EDT - 1 year ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 25, 2025, 8:05 AM EDT - 1 year ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 1 year ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Filana Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:30 AM EST - 1 year ago

Filana Therapeutics Annual report: Q4 2024

Filana Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 7:30 AM EST - 1 year ago

Filana Therapeutics Earnings release: Q4 2024

Cassava Sciences Provides a Business Update

Jan 7, 2025, 4:30 PM EST - 1 year ago

Cassava Sciences Provides a Business Update

MainStreetProdigy
MainStreetProdigy Jun. 24 at 8:09 PM
$FLNA Tick, tock, tick, tock.. ⏰ "Wise man say: Forgiveness is divine, but never pay full price for late pizza" 🍕 We’re still waiting on the PR announcing the FDA releasing their clinical hold.. THE CLOCK IS TICKING DUDE as the stock price implodes! 🤦🏼‍♂️ 💣
0 · Reply
PeterRaslow
PeterRaslow Jun. 23 at 6:34 PM
$FLNA U guys remember Tiffany and Matt nachtrab They got us good
0 · Reply
wintogether
wintogether Jun. 22 at 4:32 PM
$SPCX SAVA 2.0? $FLNA
0 · Reply
PeterRaslow
PeterRaslow Jun. 16 at 9:29 PM
$SLS this guy was posting the same on $SAVA now $FLNA he dissappeared like a shit stain in the wash, got promoted to working SLS now
0 · Reply
donrubin
donrubin Jun. 16 at 8:16 PM
$FLNA it won't move before we see Form 4's.
0 · Reply
To_De_Moon
To_De_Moon Jun. 16 at 3:54 PM
$FLNA 🔥
0 · Reply
Bricktop200
Bricktop200 Jun. 16 at 8:37 AM
$FLNA I don’t care how much red I’m seeing here, end goal is the hold being lifted which I believe it will be.
1 · Reply
focafoca99
focafoca99 Jun. 15 at 10:40 AM
$FLNA approved an amendment to its 2018 Omnibus Incentive Plan, boosting authorized shares by 4 million and extending the plan to 2030. https://www.rapidticker.com/news/flna-sec-filing-fb5490
0 · Reply
ZacksResearch
ZacksResearch Jun. 12 at 3:56 PM
$FLNA Gains 5.7% in a Month 💰 $FLNA just made its case for simufilam stronger — but the FDA hurdle remains 👀 📚 New preclinical data published in Epilepsia showed simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. 🧪 The company also highlighted its TSC-related epilepsy program at Eilat XVIII and is actively working to address the FDA’s Clinical Hold through additional pre-clinical data and protocol modifications. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/FLNA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38403&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38403
1 · Reply
PeterRaslow
PeterRaslow Jun. 11 at 4:04 PM
$FLNA we will cure Alzheimer's with simifilam
2 · Reply
Bricktop200
Bricktop200 Jun. 11 at 2:45 PM
$FLNA bullish.
0 · Reply
Swai
Swai Jun. 11 at 1:47 PM
$FLNA
2 · Reply
iaconi
iaconi Jun. 10 at 7:31 PM
$FLNA what to expect from tomorrow meeting?
2 · Reply
thedavidsonny
thedavidsonny Jun. 10 at 2:34 PM
XOS 🔥 🔥 🔥 🔥 🔥 $F $FCEL $FAAS $FIT $FLNA
0 · Reply
htothaK
htothaK Jun. 10 at 12:27 AM
$FLNA why the sudden after hours drop?
2 · Reply
Wellthen
Wellthen Jun. 9 at 5:11 PM
$FLNA The AI generated AZ treatment is likely reaping $M s. At least give Simufilam a chance. It helped people.
0 · Reply
fedeperu
fedeperu Jun. 8 at 7:56 PM
$FLNA 👀👀
0 · Reply
JumpStarting
JumpStarting Jun. 5 at 7:32 PM
$TLRY $FLNA $BNGO $SPX Good news should not be bad news!
0 · Reply
Bricktop200
Bricktop200 Jun. 5 at 8:23 AM
$FLNA insider trading in the overnight market.
1 · Reply
Bricktop200
Bricktop200 Jun. 5 at 8:12 AM
$FLNA I believe news is here and I don’t think it’s good by the way the share price is reacting.
1 · Reply
Bricktop200
Bricktop200 Jun. 5 at 6:03 AM
$FLNA price being blatantly manipulated in the over night market.
0 · Reply
Wellthen
Wellthen Jun. 4 at 8:11 PM
$FLNA I think given even modest results from the studies, simufulam should be submitted for Expanded Access — compassionate use as people have no real alternative and their is some proof it works. Also, has there been any follow up on long term users? Once any indication for this drug is approved, it will be the largest off-label drug in history.
0 · Reply